These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21890325)

  • 1. Plasma metalloproteinase levels and left ventricular remodeling in hypertrophic cardiomyopathy in patients with an identical mutation.
    Kitaoka H; Kubo T; Okawa M; Takenaka N; Baba Y; Yamasaki N; Matsumura Y; Furuno T; Doi YL
    J Cardiol; 2011 Nov; 58(3):261-5. PubMed ID: 21890325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function.
    Orn S; Manhenke C; Squire IB; Ng L; Anand I; Dickstein K
    J Card Fail; 2007 Dec; 13(10):843-9. PubMed ID: 18068618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac Myosin-binding protein C gene among Japanese.
    Kubo T; Kitaoka H; Okawa M; Matsumura Y; Hitomi N; Yamasaki N; Furuno T; Takata J; Nishinaga M; Kimura A; Doi YL
    J Am Coll Cardiol; 2005 Nov; 46(9):1737-43. PubMed ID: 16256878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene.
    Magga J; Sipola P; Vuolteenaho O; Risteli J; Jääskeläinen P; Peuhkurinen K; Kuusisto J
    Am J Cardiol; 2008 Apr; 101(8):1185-90. PubMed ID: 18394456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of metalloproteinases on left ventricular remodeling and heart failure events in patients with hypertrophic cardiomyopathy.
    Kitaoka H; Kubo T; Okawa M; Hayato K; Yamasaki N; Matsumura Y; Doi YL
    Circ J; 2010 Jun; 74(6):1191-6. PubMed ID: 20453389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular diastolic function assessed with cardiovascular magnetic resonance imaging and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy.
    Małek LA; Chojnowska L; Kłopotowski M; Misko J; Dabrowski M; Kuśmierczyk-Droszcz B; Maczyńska R; Piotrowicz E; Ruzyłło W
    Kardiol Pol; 2009 Jan; 67(1):1-6; discussion 7-8. PubMed ID: 19253184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure.
    Yan AT; Yan RT; Spinale FG; Afzal R; Gunasinghe HR; Arnold M; Demers C; McKelvie RS; Liu PP
    J Card Fail; 2006 Sep; 12(7):514-9. PubMed ID: 16952784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
    Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
    Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel cardiac myosin-binding protein C S297X mutation in hypertrophic cardiomyopathy.
    Hirota T; Kubo T; Kitaoka H; Hamada T; Baba Y; Hayato K; Okawa M; Yamasaki N; Matsumura Y; Yabe T; Doi YL
    J Cardiol; 2010 Jul; 56(1):59-65. PubMed ID: 20350521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes.
    Poutanen T; Tikanoja T; Jääskeläinen P; Jokinen E; Silvast A; Laakso M; Kuusisto J
    Am Heart J; 2006 Mar; 151(3):725.e1-725.e9. PubMed ID: 16504640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling.
    Saura D; Marín F; Climent V; González J; Roldán V; Hernández-Romero D; Oliva MJ; Sabater M; de la Morena G; Lip GY; Valdés M
    Int J Clin Pract; 2009 Oct; 63(10):1465-71. PubMed ID: 19769703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: correlation with left-ventricular volume and function.
    Suezawa C; Kusachi S; Murakami T; Toeda K; Hirohata S; Nakamura K; Yamamoto K; Koten K; Miyoshi T; Shiratori Y
    J Lab Clin Med; 2005 Jan; 145(1):33-40. PubMed ID: 15668659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exercise-induced systolic dysfunction in patients with non-obstructive hypertrophic cardiomyopathy and mutations in the cardiac troponin genes.
    Sakata K; Ino H; Fujino N; Nagata M; Uchiyama K; Hayashi K; Konno T; Inoue M; Kato H; Sakamoto Y; Tsubokawa T; Yamagishi M
    Heart; 2008 Oct; 94(10):1282-7. PubMed ID: 17923468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy.
    Maron MS; Appelbaum E; Harrigan CJ; Buros J; Gibson CM; Hanna C; Lesser JR; Udelson JE; Manning WJ; Maron BJ
    Circ Heart Fail; 2008 Sep; 1(3):184-91. PubMed ID: 19808288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction.
    Noji Y; Shimizu M; Ino H; Higashikata T; Yamaguchi M; Nohara A; Horita T; Shimizu K; Ito Y; Matsuda T; Namura M; Mabuchi H
    Circ J; 2004 Apr; 68(4):355-60. PubMed ID: 15056834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiponectin acts as a positive indicator of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy.
    Unno K; Shibata R; Izawa H; Hirashiki A; Murase Y; Yamada T; Kobayashi M; Noda A; Nagata K; Ouchi N; Murohara T
    Heart; 2010 Mar; 96(5):357-61. PubMed ID: 19648128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction.
    Matsunaga T; Abe N; Kameda K; Hagii J; Fujita N; Onodera H; Kamata T; Ishizaka H; Hanada H; Osanai T; Okumura K
    Int J Cardiol; 2005 Nov; 105(2):203-8. PubMed ID: 16243114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.